Nonetheless, in the context of the increasing use of neoadjuvant IT in TNBC patients, it is worth mentioning that we observed a trend toward fewer malignant foci to the lungs in any treatment group that included neoadjuvant ALK1-Fc in our mouse models (Supplemental Figure 1), suggesting that the molecular cues in the metastatic colonization and growth are only partially overlapping with those of the primary tumor mass. This evidence concerns the gene ALK and neoplasm.